MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Home・Akcijų sąrašas・AnaptysBio Inc

AnaptysBio Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

30.84 2.97

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.98

Max

31.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	699K -39M
Pardavimai	-5.5M 22M
Pelno marža	-173.517
Darbuotojai	136
EBITDA	9.2M -18M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+71.25% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-52M 660M
Ankstesnė atidarymo kaina	27.87
Ankstesnė uždarymo kaina	30.84

Naujienos nuotaikos

By Acuity

81%

19%

350 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

19.25 / 21.135 Palaikymas ir pasipriešinimas

AnaptysBio Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-02 23:30; UTC

Karštos akcijos

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025-10-02 21:21; UTC

Uždarbis

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025-10-03 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025-10-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025-10-02 23:39; UTC

Rinkos pokalbiai

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025-10-02 23:00; UTC

Rinkos pokalbiai

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Scales's JV Buyout Lauded by Bull -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-02 21:17; UTC

Įsigijimai, susijungimai, perėmimai

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025-10-02 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-02 20:49; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025-10-02 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025-10-02 19:20; UTC

Rinkos pokalbiai

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025-10-02 19:10; UTC

Rinkos pokalbiai

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025-10-02 19:04; UTC

Rinkos pokalbiai

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025-10-02 18:43; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Akcijų palyginimas

Kainos pokytis

AnaptysBio Inc Prognozė

Kainos tikslas

By TipRanks

71.25% į viršų

12 mėnesių prognozė

Vidutinis 53.67 USD 71.25%

Aukščiausias 90 USD

Žemiausias 20 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AnaptysBio Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių AnaptysBio Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

19.25 / 21.135Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

350 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.